Arkolith/Insider Trading/PRLD/Form 4

Vaddi Krishna

CEO, DirectorPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Mar 14, 2025
Net Buying
Open-Market Buys
$70K
Open-Market Sells
$0
Net Open-Market Flow
$70K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2025Buy(P)50K$0.72$36K1.3M
Mar 12, 2025Buy(P)48K$0.71$34K1.2M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-002392) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML